How large was the sample size in the Yenos validation studies?

The specific sample sizes used in each Yenos validation study are reported in the published papers. The 2025 study (doi:10.3390/ijms26083822) tested individual cancer patients and healthy controls with newly diagnosed Stage I and II cancer, achieving per-marker accuracy of miR-21 (93.8%, 36/37 correct), miR-375 (81.5%), and miR-141 (97.3%). The 2024 study (doi:10.3390/ncrna10040042) reports cancer samples averaging 1.83× HL (RSD 0.09) and healthy samples averaging 1.04× HL (RSD 0.17) with statistical significance of p=1.6×10⁻²². These sample sizes are comparable to or larger than early-stage validation studies for other MCED tests. Larger prospective population studies are a natural next step as the platform matures, analogous to the NHS-Galleri study for Grail's Galleri test.